U.S. markets closed
  • S&P 500

    4,455.48
    +6.50 (+0.15%)
     
  • Dow 30

    34,798.00
    +33.18 (+0.10%)
     
  • Nasdaq

    15,047.70
    -4.54 (-0.03%)
     
  • Russell 2000

    2,248.07
    -10.97 (-0.49%)
     
  • Crude Oil

    73.95
    +0.65 (+0.89%)
     
  • Gold

    1,750.60
    +0.80 (+0.05%)
     
  • Silver

    22.37
    -0.27 (-1.20%)
     
  • EUR/USD

    1.1718
    -0.0029 (-0.25%)
     
  • 10-Yr Bond

    1.4600
    +0.0500 (+3.55%)
     
  • GBP/USD

    1.3681
    -0.0040 (-0.29%)
     
  • USD/JPY

    110.6850
    +0.3840 (+0.35%)
     
  • BTC-USD

    43,217.07
    +679.07 (+1.60%)
     
  • CMC Crypto 200

    1,067.20
    -35.86 (-3.25%)
     
  • FTSE 100

    7,051.48
    -26.87 (-0.38%)
     
  • Nikkei 225

    30,248.81
    +609.41 (+2.06%)
     

Benzinga's Top Upgrades, Downgrades For December 23, 2020

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·6 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

 

Downgrades

  • Roth Capital downgraded the previous rating for Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) from Buy to Sell. Arcturus Therapeutics earned $0.92 in the third quarter, compared to $0.56 in the year-ago quarter. The stock has a 52-week-high of $129.71 and a 52-week-low of $8.51. At the end of the last trading period, Arcturus Therapeutics closed at $118.46.

  • According to BMO Capital, the prior rating for FuboTV Inc (NYSE:FUBO) was changed from Outperform to Market Perform. FuboTV earned $1.65 in the third quarter, compared to $0.25 in the year-ago quarter. The stock has a 52-week-high of $62.29 and a 52-week-low of $8.12. At the end of the last trading period, FuboTV closed at $62.19.

  • For PaySign Inc (NASDAQ:PAYS), Canaccord Genuity downgraded the previous rating of Buy to Hold. In the third quarter, PaySign showed an EPS of $0.14, compared to $0.06 from the year-ago quarter. At the moment, the stock has a 52-week-high of $10.98 and a 52-week-low of $3.63. PaySign closed at $4.91 at the end of the last trading period.

  • BMO Capital downgraded the previous rating for IAC/InterActiveCorp (NASDAQ:IAC) from Outperform to Market Perform. IAC/InterActiveCorp earned $0.11 in the third quarter, compared to $1.35 in the year-ago quarter. The current stock performance of IAC/InterActiveCorp shows a 52-week-high of $324.74 and a 52-week-low of $100.22. Moreover, at the end of the last trading period, the closing price was at $183.73.

 

Initiations

  • CMB International initiated coverage on iHuman Inc (NYSE:IH) with a Buy rating. The price target for iHuman is set to $26.08. In the third quarter, iHuman earned $0.03. At the moment, the stock has a 52-week-high of $31.58 and a 52-week-low of $16.07. iHuman closed at $21.10 at the end of the last trading period.

  • With an Outperform rating, JMP Securities initiated coverage on Evelo Biosciences Inc (NASDAQ:EVLO). The price target seems to have been set at $27.00 for Evelo Biosciences. Evelo Biosciences earned $0.45 in the third quarter, compared to $0.67 in the year-ago quarter. The stock has a 52-week-high of $11.84 and a 52-week-low of $3.01. At the end of the last trading period, Evelo Biosciences closed at $11.20.

  • Piper Sandler initiated coverage on Cogent Biosciences Inc (NASDAQ:COGT) with an Overweight rating. The price target for Cogent Biosciences is set to $22.00. In the third quarter, Cogent Biosciences showed an EPS of $0.31, compared to $1.56 from the year-ago quarter. The stock has a 52-week-high of $14.44 and a 52-week-low of $8.40. At the end of the last trading period, Cogent Biosciences closed at $12.20.

  • Benchmark initiated coverage on CC Neuberger Principal Holdings I (NYSE:PCPL) with a Buy rating. The price target for CC Neuberger Principal is set to $15.00. The current stock performance of CC Neuberger Principal shows a 52-week-high of $11.29 and a 52-week-low of $9.95. Moreover, at the end of the last trading period, the closing price was at $10.80.

  • With a Neutral rating, Baird initiated coverage on Square Inc (NYSE:SQ). The price target seems to have been set at $245.00 for Square. Square earned $0.34 in the third quarter, compared to $0.25 in the year-ago quarter. At the moment, the stock has a 52-week-high of $243.38 and a 52-week-low of $32.33. Square closed at $241.57 at the end of the last trading period.

  • With an Outperform rating, Baird initiated coverage on Qualcomm Inc (NASDAQ:QCOM). The price target seems to have been set at $200.00 for Qualcomm. In the fourth quarter, Qualcomm showed an EPS of $1.45, compared to $0.78 from the year-ago quarter. The stock has a 52-week-high of $161.07 and a 52-week-low of $58.00. At the end of the last trading period, Qualcomm closed at $146.34.

  • JMP Securities initiated coverage on Seres Therapeutics Inc (NASDAQ:MCRB) with a Market Perform rating. Seres Therapeutics earned $0.36 in the third quarter, compared to $0.23 in the year-ago quarter. At the moment, the stock has a 52-week-high of $38.50 and a 52-week-low of $2.52. Seres Therapeutics closed at $24.78 at the end of the last trading period.

  • Santander initiated coverage on Linx SA (NYSE:LINX) with a Hold rating. The price target for Linx is set to $7.60. In the third quarter, Linx showed an EPS of $0.01, compared to $0.00 from the year-ago quarter. At the moment, the stock has a 52-week-high of $9.47 and a 52-week-low of $2.83. Linx closed at $7.24 at the end of the last trading period.

  • With a Neutral rating, Baird initiated coverage on Luminar Technologies Inc (NASDAQ:LAZR). The price target seems to have been set at $30.00 for Luminar Technologies. At the moment, the stock has a 52-week-high of $47.80 and a 52-week-low of $19.10. Luminar Technologies closed at $37.37 at the end of the last trading period.

  • With a Buy rating, Stifel initiated coverage on Lithium Americas Corp (NYSE:LAC). The price target seems to have been set at $13.25 for Lithium Americas. Lithium Americas earned $0.07 in the third quarter, compared to $0.06 in the year-ago quarter. The current stock performance of Lithium Americas shows a 52-week-high of $16.97 and a 52-week-low of $1.92. Moreover, at the end of the last trading period, the closing price was at $11.35.

  • JMP Securities initiated coverage on Kaleido Biosciences Inc (NASDAQ:KLDO) with an Outperform rating. The price target for Kaleido Biosciences is set to $22.00. Kaleido Biosciences earned $0.65 in the third quarter, compared to $0.74 in the year-ago quarter. At the moment, the stock has a 52-week-high of $11.89 and a 52-week-low of $2.82. Kaleido Biosciences closed at $8.99 at the end of the last trading period.

  • With a Buy rating, CMB International initiated coverage on iQIYI Inc (NASDAQ:IQ). The price target seems to have been set at $23.20 for iQIYI. For the third quarter, iQIYI had an EPS of $0.24, compared to year-ago quarter EPS of $0.70. At the moment, the stock has a 52-week-high of $28.03 and a 52-week-low of $14.51. iQIYI closed at $16.97 at the end of the last trading period.

  • National Securities Corporation initiated coverage on Humanigen Inc (NASDAQ:HGEN) with a Buy rating. The price target for Humanigen is set to $35.00. The stock has a 52-week-high of $33.95 and a 52-week-low of $3.40. At the end of the last trading period, Humanigen closed at $20.79.

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.